
Internal Medicine News - With or without ADHD: bupropion may help reduce nicotine dependence in teens
January 12th, 2009 Adolescents with nicotine dependence may benefit from bupropion, whether or not they have comorbid attention-deficit hyperactivity disorder, said Dr. Himanshu P. Upadhyaya and colleagues at the Medical University of South Carolina, Charleston.
Bupropion slow release (SR) has been…
Clinical Psychiatry News - Counseling fails to increase rate of smoking cessation in bupropion users
January 11th, 2009 SCOTTSDALE, ARIZ. — Providing counseling on smoking cessation did not boost quit rates in patients being treated with bupropion SR, Danielle E. McCarthy reported in a poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
She and her colleagues recruited 463 adults who reported smoking at least 10 cigarettes per day and wanted to quit. Half the participants were female, and the mean age was 39 years.
The…
Clinical Psychiatry News - Bupropion and schizophrenia
January 7th, 2009 The Patient
You have a patient who suffers from schizophrenia. Positive symptoms have been well controlled with an antipsychotic for several months. He requests alleviation of his nicotine habit. You consider bupropion, but, knowing the mechanism of action of bupropion, you are concerned that positive symptoms may be exacerbated.
The Question
What is the risk of exacerbating positive…
Clinical Psychiatry News - Bupropion XL useful for adult ADHD
January 5th, 2009 BAL HARBOUR, FLA. — Extended-release bupropion appears to be a safe and effective treatment for adults with attention-deficit hyperactivity disorder, with more than 50% of patients experiencing at least a 30% reduction in core symptoms while on the drug, Dr. Joseph Horrigan reported in a poster at the annual meeting of the American Neuropsychiatric Association.
About 40%-70% of children with attention-deficit hyperact…
British Medical Journal - Bupropion for smokers
January 3rd, 2009 Bupropion may not be as good as editorial implies
EDITOR–Britton and Jarvis give a surprisingly uncritical welcome to bupropion.[1] Although Jorenby et al did find that 30% of patients who took bupropion were still non-smokers after 12 months (point prevalence data), these volunteers must have been highly motivated as 12-15% of those who took the placebo successfully stopped smoking.[2] There are no studies showing that bupropi…
Clinical Psychiatry News - Abuse of bupropion
December 30th, 2008 The Problem
You work in one of America’s contemporary long-term psychiatric treatment centers, also known as a state prison. Inmates who come to outpatient appointments and complain of depressive symptoms frequently request bupropion (Wellbutrin). The history they provide is speciously similar: “It’s the only antidepressant that’s ever worked.” You start to inquire about how this medication is …
Clinical Psychiatry News - Bupropion no help longer term
December 28th, 2008 The antidepressant bupropion hydrochloride does not significantly increase longer-term smoking cessation rates for some patients, despite several recent studies touting its use for this purpose, Dr. Joel A. Simon and his colleagues reported.
In a randomized, blinded trial conducted in the San Francisco Veterans Affairs Medical Center of 244 veterans who were moderate to heavy smokers, 121 subjects received a 7-week course of bupropion and 123 received placebo. All subjects were given 2…
Clinical Psychiatry News - Bupropion boosts smoking cessation in blacks
December 24th, 2008 The use of sustained-release bupropion can improve smoking-cessation rates in African Americans in conjunction with culturally sensitive counseling, said Dr. Jasjit S. Ahluwalia of the University of Kansas, Kansas City, and colleagues.
In what they called the larg…
Clinical Psychiatry News - Bupropion may aid weight loss
December 20th, 2008 WASHINGTON — Bupropion SR is an effective antidepressant that also may aid weight loss, investigators said at the annual scientific assembly of the Southern Medical Association.
Obese patients taking bupropion SR (Wellbutrin) lost significantly more weight than obese patient…
Business Wire - Biovail Launches Wellbutrin XL to Canadian Physicians
December 16th, 2008 TORONTO — Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that Wellbutrin(R) XL, the first once-daily extended-release formulation of bupropion hydrochloride approved for the Canadian market for the treatment of depression in adults, has been officially launched and is commercially available.
Wellbutrin(R) XL, is being marketed and distributed by Biovail Pharmaceuticals …

